First Header Logo Second Header Logo

Connection

John Parks to Gene Expression

This is a "connection" page, showing publications John Parks has written about Gene Expression.
Connection Strength

0.683
  1. Zhang P, Boudyguina E, Wilson MD, Gebre AK, Parks JS. Echium oil reduces plasma lipids and hepatic lipogenic gene expression in apoB100-only LDL receptor knockout mice. J Nutr Biochem. 2008 Oct; 19(10):655-63.
    View in: PubMed
    Score: 0.274
  2. Forrest LM, Lough CM, Chung S, Boudyguina EY, Gebre AK, Smith TL, Colvin PL, Parks JS. Echium oil reduces plasma triglycerides by increasing intravascular lipolysis in apoB100-only low density lipoprotein (LDL) receptor knockout mice. Nutrients. 2013 Jul 12; 5(7):2629-45.
    View in: PubMed
    Score: 0.101
  3. Chung S, Timmins JM, Duong M, Degirolamo C, Rong S, Sawyer JK, Singaraja RR, Hayden MR, Maeda N, Rudel LL, Shelness GS, Parks JS. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. J Biol Chem. 2010 Apr 16; 285(16):12197-209.
    View in: PubMed
    Score: 0.080
  4. Furbee JW, Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis. 2002 Nov; 165(1):89-100.
    View in: PubMed
    Score: 0.048
  5. Furbee JW, Francone O, Parks JS. Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT. J Lipid Res. 2001 Oct; 42(10):1626-35.
    View in: PubMed
    Score: 0.044
  6. Chisholm JW, Gebre AK, Parks JS. Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. J Lipid Res. 1999 Aug; 40(8):1512-9.
    View in: PubMed
    Score: 0.038
  7. Wang J, Gebre AK, Anderson RA, Parks JS. Cloning and in vitro expression of rat lecithin:cholesterol acyltransferase. Biochim Biophys Acta. 1997 Jun 23; 1346(3):207-11.
    View in: PubMed
    Score: 0.033
  8. Ma L, Mondal AK, Murea M, Sharma NK, Tönjes A, Langberg KA, Das SK, Franks PW, Kovacs P, Antinozzi PA, Stumvoll M, Parks JS, Elbein SC, Freedman BI. The effect of ACACB cis-variants on gene expression and metabolic traits. PLoS One. 2011; 6(8):e23860.
    View in: PubMed
    Score: 0.022
  9. Malloy SI, Altenburg MK, Knouff C, Lanningham-Foster L, Parks JS, Maeda N. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler Thromb Vasc Biol. 2004 Jan; 24(1):91-7.
    View in: PubMed
    Score: 0.013
  10. Shelness GS, Hou L, Ledford AS, Parks JS, Weinberg RB. Identification of the lipoprotein initiating domain of apolipoprotein B. J Biol Chem. 2003 Nov 07; 278(45):44702-7.
    View in: PubMed
    Score: 0.013
  11. DeLozier JA, Parks JS, Shelness GS. Vesicle-binding properties of wild-type and cysteine mutant forms of alpha(1) domain of apolipoprotein B. J Lipid Res. 2001 Mar; 42(3):399-406.
    View in: PubMed
    Score: 0.011
  12. Sorci-Thomas MG, Parks JS, Kearns MW, Pate GN, Zhang C, Thomas MJ. High level secretion of wild-type and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. J Lipid Res. 1996 Mar; 37(3):673-83.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.